Stockscreener 앱 받기
13.28
2.39%
-0.34
전일 마감가:
$13.62
열려 있는:
$13.48
하루 거래량:
215.25K
Relative Volume:
0.24
시가총액:
$1.10B
수익:
$288.00K
순이익/손실:
$-228.06M
주가수익비율:
-3.1247
EPS:
-4.25
순현금흐름:
$-168.82M
1주 성능:
-1.74%
1개월 성능:
+10.88%
6개월 성능:
-42.92%
1년 성능:
-13.67%
1일 변동 폭
$13.06
$13.62
1주일 범위
$12.92
$13.99
52주 변동 폭
$9.90
$27.20
Viridian Therapeutics Inc Stock (VRDN) Company Profile
명칭
Viridian Therapeutics Inc
전화
617.272.4600
주소
221 CRESCENT STREET, WALTHAM
VRDN을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
VRDN
Viridian Therapeutics Inc
|
13.30 | 1.10B | 288.00K | -228.06M | -168.82M | -4.25 |
|
VRTX
Vertex Pharmaceuticals Inc
|
502.76 | 127.64B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
606.50 | 65.95B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
655.49 | 37.92B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
268.46 | 32.98B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
254.08 | 26.89B | 3.81B | -644.79M | -669.77M | -6.24 |
Viridian Therapeutics Inc Stock (VRDN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-12-19 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2024-11-25 | 개시 | TD Cowen | Buy |
| 2024-09-11 | 재확인 | Needham | Buy |
| 2024-06-11 | 개시 | Wolfe Research | Outperform |
| 2024-06-06 | 개시 | Goldman | Buy |
| 2024-05-09 | 다운그레이드 | B. Riley Securities | Buy → Neutral |
| 2024-05-09 | 다운그레이드 | Ladenburg Thalmann | Buy → Neutral |
| 2023-06-14 | 개시 | BTIG Research | Buy |
| 2023-06-14 | 재개 | Credit Suisse | Outperform |
| 2023-05-30 | 개시 | RBC Capital Mkts | Outperform |
| 2023-04-17 | 개시 | Wells Fargo | Overweight |
| 2023-03-30 | 개시 | Stifel | Buy |
| 2022-12-19 | 개시 | Cowen | Outperform |
| 2022-12-19 | 개시 | Needham | Buy |
| 2022-12-16 | 개시 | Credit Suisse | Outperform |
| 2022-12-01 | 개시 | H.C. Wainwright | Buy |
| 2022-06-23 | 개시 | B. Riley Securities | Buy |
| 2021-11-18 | 개시 | SVB Leerink | Outperform |
| 2021-10-12 | 개시 | Evercore ISI | Outperform |
| 2021-01-25 | 개시 | Ladenburg Thalmann | Buy |
모두보기
Viridian Therapeutics Inc 주식(VRDN)의 최신 뉴스
How to Take Advantage of moves in (VRDN) - news.stocktradersdaily.com
Viridian Therapeutics Announces Inducement Grants Under Nasdaq L - GuruFocus
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | VRDN Stock News - GuruFocus
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule - marketscreener.com
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Viridian Therapeutics Inc [NASDAQ: VRDN] Sees Increase in Stock Value - knoxdaily.com
Thyroid Eye Disease Pipeline 2025: MOA, ROA, and Clinical Trial - openPR.com
Thyroid Eye Disease Pipeline 2025: MOA, ROA, and Clinical Trial Insights Explored by DelveInsight | Immunovant Sciences, Novartis, Viridian Therapeutics, Sling Therapeutics, Regeneron Pharma - Barchart.com
Viridian Therapeutics Inc (VRDN) did well last session? - uspostnews.com
Viridian Therapeutics, Inc. (NASDAQ:VRDN) Shares Purchased by Barclays PLC - Defense World
Upward Trajectory: Viridian Therapeutics Inc (VRDN) Posts a Gaine, Closing at 13.53 - DWinneX
Analysts Set Viridian Therapeutics, Inc. (NASDAQ:VRDN) PT at $35.70 - Defense World
HC Wainwright Reiterates Buy Rating for Viridian Therapeutics (NASDAQ:VRDN) - Defense World
Viridian Therapeutics Inc [VRDN] Shares Fall -1.82 % on Wednesday - knoxdaily.com
How did Viridian Therapeutics Inc (VRDN) fare last session? - uspostnews.com
Viridian Therapeutics, Inc. (NASDAQ:VRDN) Shares Sold by JPMorgan Chase & Co. - Defense World
Geode Capital Management LLC Has $31.81 Million Position in Viridian Therapeutics, Inc. (NASDAQ:VRDN) - Defense World
Thyroid Eye Disease Market Predicted to See Upsurge Through - openPR.com
Retinitis Pigmentosa Market Growth to Accelerate in Forecast - openPR.com
Retinitis Pigmentosa Market Growth to Accelerate in Forecast Period (2024-2034), DelveInsight Analyzes | SparingVision SAS, ProQR Therapeutics NV, Viridian Therapeutics Inc, 4D Molecular Therapeutics - Barchart.com
Sector Update: Health Care - TradingView
Graves Ophthalmopathy Therapeutics Market Size in 7MM - openPR.com
Viridian Therapeutics, Inc. (NASDAQ:VRDN) Stock Position Lifted by Vanguard Group Inc. - Defense World
American Century Companies Inc. Has $2.18 Million Position in Viridian Therapeutics, Inc. (NASDAQ:VRDN) - Defense World
KLP Kapitalforvaltning AS Acquires New Stake in Viridian Therapeutics, Inc. (NASDAQ:VRDN) - Defense World
Viridian Therapeutics Appoints Jeff Ajer To Board - citybiz
Viridian Therapeutics Appoints Jeff Ajer to its Board of Directors - BioSpace
Viridian Therapeutics Appoints Jeff Ajer to Board - TipRanks
Viridian Therapeutics appoints Jeff Ajer to board - Investing.com
Viridian Therapeutics appoints Jeff Ajer to board By Investing.com - Investing.com UK
Viridian Therapeutics, Inc. (NASDAQ:VRDN) Shares Purchased by Corebridge Financial Inc. - Defense World
Stifel maintains Buy on Viridian Therapeutics, $41 target By Investing.com - Investing.com Canada
(VRDN) Trading Report - news.stocktradersdaily.com
Teacher Retirement System of Texas Boosts Stock Position in Viridian Therapeutics, Inc. (NASDAQ:VRDN) - Defense World
Financial Analysis: Viridian Therapeutics (NASDAQ:VRDN) versus ACI Global (OTCMKTS:ACGJ) - Defense World
Quantbot Technologies LP Invests $164,000 in Viridian Therapeutics, Inc. (NASDAQ:VRDN) - Defense World
Viridian Therapeutics, Inc. (NASDAQ:VRDN) Shares Acquired by Swiss National Bank - Defense World
Raymond James Financial Inc. Makes New $6.02 Million Investment in Viridian Therapeutics, Inc. (NASDAQ:VRDN) - Defense World
Where are the Opportunities in (VRDN) - news.stocktradersdaily.com
Charles Schwab Investment Management Inc. Raises Stock Position in Viridian Therapeutics, Inc. (NASDAQ:VRDN) - Defense World
AlphaQuest LLC Acquires 1,519 Shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN) - Defense World
Commit To Buy Viridian Therapeutics At $12.50, Earn 13.2% Annualized Using Options - Nasdaq
Viridian Therapeutics, Inc. (NASDAQ:VRDN) Receives Average Recommendation of “Moderate Buy” from Analysts - Defense World
Viridian Therapeutics, Inc. (NASDAQ:VRDN) Shares Purchased by Bank of New York Mellon Corp - Defense World
Viridian Therapeutics, Inc. (NASDAQ:VRDN) Shares Bought by Arizona State Retirement System - Defense World
410,440 Shares in Viridian Therapeutics, Inc. (NASDAQ:VRDN) Acquired by Victory Capital Management Inc. - Defense World
Viridian Therapeutics at Leerink’s Conference: Progress in TED Treatments By Investing.com - Investing.com UK
Viridian Therapeutics appoints new director, sees board resignation By Investing.com - Investing.com South Africa
Viridian Therapeutics Announces Inducement Stock Option Grants - Nasdaq
Viridian Therapeutics appoints new director, sees board resignation - Investing.com India
Viridian Therapeutics Inc (VRDN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.35%
0.36%
자본화:
|
볼륨(24시간):